- Q1 2025 revenue reached $186 million, a 62% increase over Q1 2024.
- Illuccix sales climbed 35% year-over-year to $151 million.
- FDA approved Gozellix with a planned US launch in Q2 2025.
Telix Pharmaceuticals (TLX, Financial) reported impressive financial results for the first quarter of 2025 with unaudited revenue reaching $186 million, marking a 62% increase year-over-year and a 31% rise from the previous quarter. This growth was primarily driven by two key factors. Sales of Illuccix®, a prostate cancer imaging agent, accounted for $151 million, which is a 35% year-over-year increase and an 9% increase quarter-over-quarter. The recent acquisition of RLS Radiopharmacies contributed an additional $33 million to the revenue since the completion of the acquisition on January 27, 2025.
Telix has reaffirmed its revenue guidance for the fiscal year 2025, projecting between $770 million and $800 million, considering the continued growth in Illuccix sales and the revenue from RLS. This guidance does not yet include potential earnings from the newly FDA-approved Gozellix® for prostate cancer, set to launch in the US market in Q2 2025, or anticipated sales of Illuccix in international markets.
In addition to financial growth, the company has made significant strides in its clinical and regulatory efforts. The approval of Gozellix® by the FDA marks Telix as the only company with two FDA-approved PSMA-PET imaging agents for prostate cancer, offering competitive advantages in expanded market reach and distribution capabilities. The company's kidney cancer imaging candidate, TLX250-CDx (Zircaix®), has been granted Priority Review by the FDA, with a PDUFA date set for August 27, 2025, indicating strong regulatory momentum.
Strategic developments also include the successful integration of RLS Radiopharmacies and Telix's ongoing efforts to expand its global footprint. Illuccix has received marketing authorizations across several European markets, the UK, and Brazil, with commercial launches expected to begin in Q2 2025. These expansions are set to diversify the company's revenue streams beyond the US market and further solidify its position in the global radiopharmaceutical industry.
